<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568345</url>
  </required_header>
  <id_info>
    <org_study_id>191.837</org_study_id>
    <nct_id>NCT02568345</nct_id>
  </id_info>
  <brief_title>Sugammadex ED90 Dose in the Obese Patients</brief_title>
  <official_title>Sugammadex ED90 Dose to Reverse the Rocuronium Blockade in the Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculdade de Ciências Médicas da Santa Casa de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculdade de Ciências Médicas da Santa Casa de São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the minimum effective dose of sugammadex, an
      antagonist of neuromuscular blockade used during anesthesia practice, in obese patients,
      considering that sugammadex is indicated in adults with normal weight at a dose of 2 mg/kg
      but no studies were found with obese patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective study with the sequential design method up-and-down of the biased coin aimed to
      determine the minimum effective dose in 90% of patients (ED90).

      The following doses were chosen: 2.0 mg.kg-1, 2.2 mg.kg-1, 2.4 mg.kg-1, 2.6 mg.kg-1, 2.8
      mg.kg-1.

      The complete reversal of moderate rocuronium-induced neuromuscular blockade (NMB) considered
      a T4/T1 ratio ≥ 0.9 with the peripheral nerve stimulator and accelerometer (monitor of
      sequential electric stimuli) &quot;train-of-four&quot; (TOF).

      After induction of general anesthesia and the calibration of the peripheral nerve stimulator
      and accelerometer, rocuronium 0.6 mg.kg-1 was injected.

      Continuous intravenous infusion of the anesthetics propofol and remifentanil, and
      intermittent bolus of rocuronium were offered throughout the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sugammadex ED90</measure>
    <time_frame>8 minutes</time_frame>
    <description>Complete reversal of neuromuscular blockade occured when the patient had a TOF T4/T1 ≥ 0.9 within eight minutes of sugammadex infusion.
The sequencial design method of up-and-down was applied to determine the minimum effective dose in 90% of patients (ED90). An effective dose is one that achieves complete reversal of neuromuscular blockade that is defined as a measure of TOF equal or higher than 0.9, or a relationship between T4 an T1 measure ≥ 0.9, within eight minutes of sugammadex infusion.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Incomplete Reversal of Neuromuscular Block</condition>
  <arm_group>
    <arm_group_label>sugammadex ED90</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).
The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugammadex ED90</intervention_name>
    <description>The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.
In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg.</description>
    <arm_group_label>sugammadex ED90</arm_group_label>
    <other_name>ED90</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a body mass index ≥ 40 kg/m2

          -  bariatric surgery

          -  informed consent signed

        Exclusion Criteria:

          -  history of neuromuscular diseases,

          -  use of drugs that could interfere with neuromuscular transmission,

          -  allergy to neuromuscular agents of the aminosteroids class,

          -  anticipated difficulty in airway management,

          -  renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lígia Andrade ST Mathias, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Full professor</affiliation>
  </overall_official>
  <reference>
    <citation>1983 metropolitan height and weight tables. Stat Bull Metrop Life Found. 1983 Jan-Jun;64(1):3-9.</citation>
    <PMID>6623350</PMID>
  </reference>
  <reference>
    <citation>Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet. 1984 Mar-Apr;9(2):177-83.</citation>
    <PMID>6143633</PMID>
  </reference>
  <reference>
    <citation>Blouin RA, Kolpek JH, Mann HJ. Influence of obesity on drug disposition. Clin Pharm. 1987 Sep;6(9):706-14. Review.</citation>
    <PMID>3315402</PMID>
  </reference>
  <reference>
    <citation>de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007 Aug;107(2):239-44.</citation>
    <PMID>17667567</PMID>
  </reference>
  <reference>
    <citation>Donati F. Sugammadex: a cyclodextrin to reverse neuromuscular blockade in anaesthesia. Expert Opin Pharmacother. 2008 Jun;9(8):1375-86. doi: 10.1517/14656566.9.8.1375 . Review.</citation>
    <PMID>18473711</PMID>
  </reference>
  <reference>
    <citation>Duffull SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CM. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet. 2004;43(15):1167-78.</citation>
    <PMID>15568893</PMID>
  </reference>
  <reference>
    <citation>Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003 Sep;99(3):632-7; discussion 6A.</citation>
    <PMID>12960547</PMID>
  </reference>
  <reference>
    <citation>Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051-65.</citation>
    <PMID>16176118</PMID>
  </reference>
  <reference>
    <citation>Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987 Oct 22;317(17):1098.</citation>
    <PMID>3657876</PMID>
  </reference>
  <reference>
    <citation>Nicholson WT, Sprung J, Jankowski CJ. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy. 2007 Aug;27(8):1181-8. Review.</citation>
    <PMID>17655516</PMID>
  </reference>
  <reference>
    <citation>Pai MP, Paloucek FP. The origin of the &quot;ideal&quot; body weight equations. Ann Pharmacother. 2000 Sep;34(9):1066-9.</citation>
    <PMID>10981254</PMID>
  </reference>
  <reference>
    <citation>Renes SH, van Geffen GJ, Rettig HC, Gielen MJ, Scheffer GJ. Minimum effective volume of local anesthetic for shoulder analgesia by ultrasound-guided block at root C7 with assessment of pulmonary function. Reg Anesth Pain Med. 2010 Nov-Dec;35(6):529-34. doi: 10.1097/AAP.0b013e3181fa1190.</citation>
    <PMID>20975468</PMID>
  </reference>
  <reference>
    <citation>Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006 Apr;104(4):667-74.</citation>
    <PMID>16571960</PMID>
  </reference>
  <reference>
    <citation>Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics. 2002 Mar;58(1):171-7.</citation>
    <PMID>11890313</PMID>
  </reference>
  <results_reference>
    <citation>Demirkaya M, Kelsaka E, Sarihasan B, Bek Y, Üstün E. The optimal dose of remifentanil for acceptable intubating conditions during propofol induction without neuromuscular blockade. J Clin Anesth. 2012 Aug;24(5):392-7. doi: 10.1016/j.jclinane.2011.11.006.</citation>
    <PMID>22748212</PMID>
  </results_reference>
  <results_reference>
    <citation>Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. 2006;3(1):57-71.</citation>
    <PMID>16539090</PMID>
  </results_reference>
  <results_reference>
    <citation>George RB, McKeen D, Chaplin AC, McLeod L. Up-down determination of the ED(90) of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing Cesarean delivery. Can J Anaesth. 2010 Jun;57(6):578-82. doi: 10.1007/s12630-010-9297-1. Epub 2010 Mar 18.</citation>
    <PMID>20238255</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta PK, Hopkins PM. Effect of concentration of local anaesthetic solution on the ED₅₀ of bupivacaine for supraclavicular brachial plexus block. Br J Anaesth. 2013 Aug;111(2):293-6. doi: 10.1093/bja/aet033. Epub 2013 Mar 26.</citation>
    <PMID>23533252</PMID>
  </results_reference>
  <results_reference>
    <citation>Hammer GB, Litalien C, Wellis V, Drover DR. Determination of the median effective concentration (EC50) of propofol during oesophagogastroduodenoscopy in children. Paediatr Anaesth. 2001;11(5):549-53.</citation>
    <PMID>11696118</PMID>
  </results_reference>
  <results_reference>
    <citation>Hennebry MC, Stocks GM, Belavadi P, Barnes J, Wray S, Columb MO, Lyons G. Effect of i.v. phenylephrine or ephedrine on the ED50 of intrathecal bupivacaine with fentanyl for caesarean section. Br J Anaesth. 2009 Jun;102(6):806-11. doi: 10.1093/bja/aep095. Epub 2009 May 2.</citation>
    <PMID>19411667</PMID>
  </results_reference>
  <results_reference>
    <citation>Kodaka M, Suzuki T, Maeyama A, Koyama K, Miyao H. Gender differences between predicted and measured propofol C(P50) for loss of consciousness. J Clin Anesth. 2006 Nov;18(7):486-9.</citation>
    <PMID>17126774</PMID>
  </results_reference>
  <results_reference>
    <citation>Llauradó S, Sabaté A, Ferreres E, Camprubí I, Cabrera A. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology. 2012 Jul;117(1):93-8. doi: 10.1097/ALN.0b013e3182580409.</citation>
    <PMID>22549697</PMID>
  </results_reference>
  <results_reference>
    <citation>Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a précis of clinical use, study design, and dose estimation in anesthesia research. Anesthesiology. 2007 Jul;107(1):144-52. Review.</citation>
    <PMID>17585226</PMID>
  </results_reference>
  <results_reference>
    <citation>Stylianou M, Proschan M, Flournoy N. Estimating the probability of toxicity at the target dose following an up-and-down design. Stat Med. 2003 Feb 28;22(4):535-43.</citation>
    <PMID>12590412</PMID>
  </results_reference>
  <results_reference>
    <citation>Taha AM, Abd-Elmaksoud AM. Lidocaine use in ultrasound-guided femoral nerve block: what is the minimum effective anaesthetic concentration (MEAC90)? Br J Anaesth. 2013 Jun;110(6):1040-4. doi: 10.1093/bja/aes595. Epub 2013 Feb 5.</citation>
    <PMID>23384731</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Lancker P, Dillemans B, Bogaert T, Mulier JP, De Kock M, Haspeslagh M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia. 2011 Aug;66(8):721-5. doi: 10.1111/j.1365-2044.2011.06782.x. Epub 2011 Jun 21.</citation>
    <PMID>21692760</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <results_first_submitted>October 6, 2015</results_first_submitted>
  <results_first_submitted_qc>January 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2016</results_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculdade de Ciências Médicas da Santa Casa de São Paulo</investigator_affiliation>
    <investigator_full_name>Mauro Prado da Silva</investigator_full_name>
    <investigator_title>MD, Staff</investigator_title>
  </responsible_party>
  <keyword>Dose-Response Relationship</keyword>
  <keyword>Drug</keyword>
  <keyword>Obesity</keyword>
  <keyword>Cyclodextrins</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sugammadex ED90</title>
          <description>Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).
The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg.
sugammadex ED90: The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.
In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated at 2.2 mg/kg</title>
              <participants_list>
                <participants group_id="P1" count="3">patients: 6th, 20th, 26th</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated at 2.4 mg/kg</title>
              <participants_list>
                <participants group_id="P1" count="25">Patients: 1st-5th; 7th; 11th-15th; 21st-25th; 27th-31st</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated at 2.6 mg/kg</title>
              <participants_list>
                <participants group_id="P1" count="3">Patients: 8th-10th</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugammadex ED90</title>
          <description>Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).
The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg.
sugammadex ED90: The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.
In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="35" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>body mass index: kg.m^2</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" lower_limit="44.3" upper_limit="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sugammadex ED90</title>
        <description>Complete reversal of neuromuscular blockade occured when the patient had a TOF T4/T1 ≥ 0.9 within eight minutes of sugammadex infusion.
The sequencial design method of up-and-down was applied to determine the minimum effective dose in 90% of patients (ED90). An effective dose is one that achieves complete reversal of neuromuscular blockade that is defined as a measure of TOF equal or higher than 0.9, or a relationship between T4 an T1 measure ≥ 0.9, within eight minutes of sugammadex infusion.</description>
        <time_frame>8 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugammadex ED90</title>
            <description>Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).
The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg.
sugammadex ED90: The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.
In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Sugammadex ED90</title>
          <description>Complete reversal of neuromuscular blockade occured when the patient had a TOF T4/T1 ≥ 0.9 within eight minutes of sugammadex infusion.
The sequencial design method of up-and-down was applied to determine the minimum effective dose in 90% of patients (ED90). An effective dose is one that achieves complete reversal of neuromuscular blockade that is defined as a measure of TOF equal or higher than 0.9, or a relationship between T4 an T1 measure ≥ 0.9, within eight minutes of sugammadex infusion.</description>
          <units>mg/kg</units>
          <param>Number</param>
          <dispersion>99% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" lower_limit="2.20" upper_limit="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>isotonic regression functions through PA</param_type>
            <param_value>2.20</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sugammadex ED90</title>
          <description>Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).
The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg.
sugammadex ED90: The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.
In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mauro Prado da Silva</name_or_title>
      <organization>Central Hospital, Irmandade da Santa Casa de Misericórdia (ISCM)</organization>
      <phone>+55 11 2176 7000</phone>
      <email>comissaocientifica@fcmsantacasasp.edu.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

